ALC.6 | A041501

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

Status

Recruiting

JCP

ALC.6

NCT

NCT03150693

LY.18 (ML40080, A17-190)

Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma

Status

Opening Soon

JCP

LY18

NCT

NCT04161248

LY.16

A Phase 3 Open Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy Followed by Rituximab in Subjects With Previously Untreated Follicular Lymphoma (RELEVANCE)

Status

Closed to Accrual

JCP

LY.16

NCT

NCT01650701

P16-489 | DEVOTE

Study to Describe the Management and the Use of Healthcare Resources in Patients With Chronic Lymphocytic Leukemia (CLL) Initiating Venetoclax in Routine Clinical Practice (DEVOTE)

Status

Closed to Accrual

JCP

Devote

NCT

NCT03310190